BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

参考资料： [1] New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive ...

Morales’s protocol of 6-weekly intravesical instillations of bacillus Calmette–Guerin (BCG), introduced in 1976, has survived to this date. BCG is superior to chemotherapy as an adjuvant agent ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Options for BCG-unresponsive NMIBC have expanded dramatically in the last few years. While it used to be that options were limited to regular intravesical chemotherapy or surgery, that changed ...

Ferring’s Adstiladrin became the first intravesical oncologic virus approved by the FDA for BCG-Unresponsive NMIBC CIS in 2023. Health Canada gave its approval a year earlier in 2022.

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

Intravesical BCG therapy: Widely used for treating bladder cancer. BCG vaccine for TB prevention: Traditionally administered to infants and children. In recent years, there has been a growing ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...